A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
申请人:Metabasis Therapeutics Inc.
公开号:EP1143955A3
公开(公告)日:2002-08-28
[EN] A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES<br/>[FR] COMBINAISON D'INHIBITEURS DE LA FBPase ET DE SENSIBILISANTS A L'INSULINE, POUR LE TRAITEMENT DU DIABETE
申请人:METABASIS THERAPEUTICS INC
公开号:WO2000038666A2
公开(公告)日:2000-07-06
Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.
Electrochemical Properties of Ru Polypyridyl Phosphonates
作者:Hashini N. K. Herath、Austin L. MacRae、Angel Ugrinov、Glenn R. Morello、Alexander R. Parent
DOI:10.1002/ejic.202200747
日期:——
Ru complexes containing polypyridyl phosphonate ligands were synthesized and characterized spectroscopically and electrochemically. Each compound was found to exhibit proton-coupled electron transfer (PCET).